Panmira appoints chief executive

Hari Kumar will oversee inflammation portfolio

Panmira Pharmaceuticals, a developer of therapies for inflammatory diseases, based in San Diego, California, US, has appointed Hari Kumar as chief executive.

Until recently, Kumar was chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.

Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb.

Kumar and his team will oversee Panmira's inflammation portfolio, which features a CRTH2 programme. The leading candidate, AM211, has demonstrated inhibition of eosinophils over 24 hours following oral, once-daily dosing in Phase I studies.

The firm says CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis.

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development

iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases

The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development
Subscribe now